Advance Therapy Revenue and Competitors
Estimated Revenue & Valuation
- Advance Therapy's estimated annual revenue is currently $10.4M per year.
- Advance Therapy's estimated revenue per employee is $216,000
Employee Data
- Advance Therapy has 48 Employees.
- Advance Therapy grew their employee count by 20% last year.
Advance Therapy's People
Name | Title | Email/Phone |
---|---|---|
1 | Speech-Language Pathologist - CF | Reveal Email/Phone |
Advance Therapy Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $342.8M | 907 | -6% | N/A | N/A |
#2 | $7.3M | 34 | -3% | N/A | N/A |
#3 | $23.2M | 86 | -4% | N/A | N/A |
#4 | $63.9M | 215 | 32% | N/A | N/A |
#5 | $54.1M | 182 | 18% | N/A | N/A |
#6 | $23M | 85 | 2% | N/A | N/A |
#7 | $115.4M | 342 | 7% | N/A | N/A |
#8 | $133.3M | 395 | 3% | N/A | N/A |
#9 | $16.5M | 68 | -11% | N/A | N/A |
#10 | $801.9M | 2077 | 4% | $779M | N/A |
What Is Advance Therapy?
Advance Therapy is a hospital & health care company based out of 1415 E Colorado St # 212, Glendale, California, United States.
keywords:N/AN/A
Total Funding
48
Number of Employees
$10.4M
Revenue (est)
20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Advance Therapy News
2022-04-20 - Coeptis Combines with Bull Horn in SPAC Deal to Advance ...
CD38-GEAR-NK is a natural killer (NK) cell- based therapy candidate that supports combination treatment with anti-CD38 monoclonal antibodies (...
2022-04-19 - Novel CAR T Therapy for Solid Tumors: 'Exciting Advance'
Now, a new CAR T construct that targets the tumor-specific antigen claudin 6 (CLDN6) is showing promising preliminary activity against relapsed...
2022-04-13 - Cell therapy biotech raises $120M to advance therapy to treat common cornea
condition
Aurion Biotech has raised $120 million to advance its cell therapy for an eye disorder that affects millions of people.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $10.4M | 48 | -2% | N/A |
#2 | $1.7M | 48 | 4% | N/A |
#3 | $10.6M | 49 | 4% | N/A |
#4 | $8.2M | 49 | -2% | N/A |
#5 | $8.2M | 50 | 0% | N/A |